Cash Flow Statement

Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Account Payables Change in Cash Change in Intangibles Change in Working Capital Exchange Rate Effect Free Cash Flow Gains from Investment Securities Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Income Sales of Property, Plant and Equipment

Daily Values

Growth Metrics

Others

Ratios

Innate Pharma (IPHA) Gains from Sales and Divestitures (2021 - 2025)

Historic Gains from Sales and Divestitures for Innate Pharma (IPHA) over the last 5 years, with Q2 2025 value amounting to $4.9 million.